Novel drugs and their targets in the potential treatment of diabetic retinopathy

Medical Science Monitor

Volumn 19, Issue 1, 2013, Pages 300-308

  Nawaz, Mohd Imtiaz ^a   Abouammoh, Marwan ^a   Khan, Haseeb A ^b   Alhomida, Abdullah S ^b   Alfaran, Mubarak F ^a   Ola, Mohammad Shamsul ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Diabetic retinopathy; Drugs; Hyperglycemia; Neurodegeneration; Oxidative stress; Retina

Indexed keywords

ACETYLSALICYLIC ACID; AMINOGUANIDINE; BAICALEIN; CANDESARTAN; CANDESARTAN HEXETIL; CELECOXIB; CORTICOSTEROID; DEHYDROXYMETHYLEPOXYQUINOMICIN; EPALRESTAT; FENOFIBRATE; FIDARESTAT; GENISTEIN; LIDORESTAT; LISINOPRIL; LOSARTAN; MIDOSTAURIN; NEPAFENAC; PERINDOPRIL; PONALRESTAT; PYRIDOXAMINE; RANIRESTAT; RUBOXISTAURIN; SALAZOSULFAPYRIDINE; SALICYLATE SODIUM; SORBINIL; TOLRESTAT; UNINDEXED DRUG; VALSARTAN; ZENARESTAT; ZOPOLRESTAT;

BLEEDING; BLOOD PRESSURE; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG POTENCY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INFLAMMATION; METABOLIC STRESS; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SCAR FORMATION; STEM CELL; VISUAL IMPAIRMENT; VITRECTOMY;

EID: 84876862053     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.883895     Document Type: Review

References (102)

1. World Health Organization (www.who.int). Geneva. Diabetes fact sheet number 312. [updated on 2011 Aug]; http://www.who.int/mediacentre/factsheets/fs312/en
2. Cheung N, Mitchell P, Wong TY: Diabetic retinopathy. Lancet, 2010; 376: 124-36
3. Ola MS, Nawaz MI, Siddiquei MM et al: Recent advances in understanding the biochemical and molecular mechanism of diabetic retinopathy. J Diabetes Complications, 2012; 26: 56-64
4. Porta M, Maldari P, Mazzaglia F: New approaches to the treatment of diabetic retinopathy. Diabetes ObesMetab, 2011; 13: 784-90
5. Milne R, Brownstein S: Advanced glycation end products and diabetic retinopathy. Amino Acids, 2011; [Epub ahead of print]
6. Goldin A, Beckman JA, Schmidt AM, Creager MA: Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation, 2006; 114: 597-605
7. Al-Mesallamy HO, Hammad LN, El-Mamoun TA, Khalil BM: Role of advanced glycation end product receptors in the pathogenesis of diabetic retinopathy. J Diabetes Complications, 2011; 25: 168-74
8. Kern TS, Engerman RL: Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. Diabetes, 2001; 50: 1636-42
9. Stitt A, Gardiner TA, Alderson NL et al: The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes, 2002; 51: 2826-32
10. Thallas-Bonke V, Thorpe SR, Coughlan MT et al: Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes, 2008; 57: 460-69
11. Bhatwadekar A, Glenn JV, Figarola JL et al: A new advanced glycation inhibitor, LR-90, prevents experimental diabetic retinopathy in rats. Br J Ophthalmol, 2008; 92: 545-47
12. Kaji Y, Usui T, Ishida S et al: Inhibition of diabetic leukostasis and bloodretinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol Vis Sci, 2007; 48: 858-65
13. Yamagishi S, Matsui T, Nakamura K et al: Pigment-epithelium-derived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats. Ophthalmic Res, 2007; 39: 92-97
14. Yamagishi S: Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications. Ther Apher Dial, 2009; 13: 534-39
15. Yamagishi S: Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol, 2011; 46: 217-24
16. Geraldes P, King GL: Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res, 2010; 106: 1319-31
17. Campochiaro PA; C99-PKC412-003 Study Group: Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol Vis Sci, 2004; 45: 922-31
18. Danis RP, Sheetz MJ: Ruboxistaurin: PKC-beta inhibition for complications of diabetes. Expert Opin Pharmacother, 2009; 10: 2913-25
19. Aiello LP, Bursell SE, Clermont A et al: Vascular endothelial growth factorinduced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes, 1997; 46: 1473-80
20. The PKC-DRS Study Group: The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes, 2005; 54: 2188-97
21. Davis MD, Sheetz MJ, Aiello LP et al., PKC-DRS2 Study Group: Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema. Invest Ophthalmol Vis Sci, 2009; 50: 1-4
22. The PKC-DRS2 Study Group: The effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology, 2006; 113: 2221-30
23. Aiello LP, Vignati L, Sheetz MJ et al, PKC-DRS and PKC-DRS2 Study Groups: Oral protein kinase c b inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2. Retina, 2011; 31: 2084-94
24. Lorenzi M: The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive and resilient. Exp Diabetes Res, 2007; 2007: 61038
25. Chung SS, Ho EC, Lam KS, Chung SK: Contribution of polyol pathway to diabetes-induced oxidative stress. J Am Soc Nephrol, 2003; (8 Suppl.3): S233-36
26. Chung SS, Chung SK: Aldose reductase in diabetic microvascular complications. Curr Drug Targets, 2005; 6: 475-86
27. Obrosova IG, Minchenko AG, Vasupuram R et al: Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes, 2003; 52: 864-71
28. Sun W, Oates PJ, Coutcher JB et al: A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Diabetes, 2006; 55: 2757-62
29. Drel VR, Pacher P, Ali TK et al: Aldose reductase inhibitor fidarestat counteracts diabetes-associated cataract formation, retinal oxidative-nitrosative stress, glial activation, and apoptosis. Int J Mol Med, 2008; 21: 667-76
30. Mohamed Q, Wong TY: Emerging drugs for diabetic retinopathy. Expert Opin Emerg Drugs, 2008; 13: 675-94
31. Hotta N, Kawamori R, Atsumi Y et al., ADCT Study Group: Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat. Diabet Med, 2008; 25: 818-25
32. Hattori T, Matsubara A, Taniguchi K, Ogura Y: Aldose reductase inhibitor fidarestat attenuates leukocyte-endothelial interactions in experimental diabetic rat retina in vivo. Curr Eye Res, 2010; 35: 146-54
33. Saraswat M, Muthenna P, Suryanarayana P et al: Dietary sources of aldose reductase inhibitors: prospects for alleviating diabetic complications. Asia Pac J Clin Nutr, 2008; 17: 558-65
34. Gacche RN, Dhole NA: Profile of aldose reductase inhibition, anti-cataract and free radical scavenging activity of selected medicinal plants: an attempt to standardize the botanicals for amelioration of diabetes complications. Food Chem Toxicol, 2011; 49: 1806-13
35. Adamis AP, Berman AJ: Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol, 2008; 30: 65284
36. Abu El-Asrar AM, Al-Mezaine HS, Ola MS: Pathophysiology and management of diabetic retinopathy. Expert Rev Ophthalmol, 2008; 4: 627-47
37. Zhang W, Liu H, Al-Shabrawey M et al: Inflammation and diabetic retinal microvascular complications. J Cardiovasc Dis Res, 2011; 2: 96-103
38. Sun W, Gerhardinger C, Dagher Z et al: Aspirin at low-intermediate concentrations protects retinal vessels in experimental diabetic retinopathy through non-platelet-mediated effects. Diabetes, 2005; 54: 3418-26
39. Joussen AM, Poulaki V, Mitsiades N et al: Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-αlpha suppression. FASEB J, 2002; 16: 438-40
40. Kern TS, Miller CM, Du Y et al: Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes, 2007; 56: 373-79
41. Zheng L, Howell SJ, Hatala DA et al: Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes, 2007; 56: 337-45
42. Amrite AC, Ayalasomayajula SP, Cheruvu NP, Kompella UB: Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest Ophthalmol Vis Sci, 2006; 47: 1149-60
43. Zheng L, Kern TS: Role of nitric oxide, superoxide, peroxynitrite and PARP in diabetic retinopathy. Front Biosci, 2009; 14: 3974-87
44. Yang LP, Sun HL, Wu LM et al: Baicalein reduces inflammatory process in a rodent model of diabetic retinopathy. Invest Ophthalmol Vis Sci, 2009; 50: 2319-27
45. Ibrahim AS, El-Shishtawy MM, Peña A Jr, Liou GI: Genistein attenuates retinal inflammation associated with diabetes by targeting of microglial activation. Mol Vis, 2010; 16: 2033-42
46. Zheng L, Szabó C, Kern TS: Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB. Diabetes, 2004; 53: 2960-67
47. Sugawara R, Hikichi T, Kitaya N et al: Peroxynitrite decomposition catalyst, FP15, and poly(ADP-ribose) polymerase inhibitor, PJ34, inhibit leukocyte entrapment in the retinal microcirculation of diabetic rats. Curr Eye Res, 2004; 29: 11-16
48. Drel VR, Xu W, Zhang J et al: Poly(ADP-ribose)polymerase inhibition counteracts cataract formation and early retinal changes in streptozotocin-diabetic rats. Invest Ophthalmol Vis Sci, 2009; 50: 1778-90
49. Harada C, Okumura A, Namekata K et al: Role of monocyte chemotactic protein-1 and nuclear factor kappa B in the pathogenesis of proliferative diabetic retinopathy. Diabetes Res ClinPract, 2006; 74: 249-56
50. Nagai N, Izumi-Nagai K, Oike Y et al: Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway. Invest Ophthalmol Vis Sci, 2007; 48: 4342-50
51. Kowluru RA, Tang J, Kern TS: Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII. Effect of long-term administration of antioxidants on the development of retinopathy. Diabetes, 2001; 50: 1938-42
52. Mori F, Hikichi T, Nagaoka T et al: Inhibitory effect of losartan, an AT1 angiotensin II receptor antagonist, on increased leucocyte entrapment in retinal microcirculation of diabetic rats. Br J Ophthalmol, 2002; 86: 1172-7453.
53. Poma P, Notarbartolo M, Labbozzetta M et al: Antitumor effects of the novel NF-kappaBinhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production. Int J Oncol, 2006; 28: 923-30
54. Yoshida A, Yoshida S, Ishibashi T et al: Suppression of retinal neovascularization by the NF-kappaB inhibitor pyrrolidinedithiocarbamate in mice. Invest Ophthalmol Vis Sci, 1999; 40: 1624-29
55. Noma H, Funatsu H, Mimura T et al: Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology, 2009; 116: 87293
56. Satofuka S, Ichihara A, Nagai N et al: (Pro)renin receptor-mediated signal transduction and tissue renin-angiotensin system contribute to diabetesinduced retinal inflammation. Diabetes, 2009; 58: 1625-33
57. Zhang X, Lassila M, Cooper ME, Cao Z: Retinal expression of vascular endothelial growth factor is mediated by angiotensin type 1 and type 2 receptors. Hypertension, 2004; 43: 276-81
58. Gao BB, Phipps JA, Bursell D et al: Angiotensin AT1 receptor antagonism ameliorates murine retinal proteome changes induced by diabetes. J Proteome Res, 2009; 8: 5541-49
59. Wu X, Kihara T, Hongo H et al: Angiotensin receptor type 1 antagonists protect against neuronal injury induced by oxygen-glucose depletion. Br J Pharmacol, 2010; 161: 33-50
60. Liu H, Kitazato KT, Uno M et al: Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: in-vivo and in-vitro studies. J Hypertens, 2008; 26: 1435-45
61. Chen P, Scicli GM, Guo M et al: Role of angiotensin II in retinal leukostasis in the diabetic rat. Exp Eye Res, 2006; 83: 1041-51
62. Egami K, Murohara T, Shimada T et al: Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest, 2003; 112: 67-75
63. Chaturvedi N, Sjolie AK, Stephenson JM et al: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin- Dependent Diabetes Mellitus. Lancet, 1998; 351: 28-31
64. Zheng Z, Chen H, Ke G et al: Protective effect of perindopril on diabetic retinopathy is associated with decreased vascular endothelial growth factorto- pigment epithelium-derived factor ratio: involvement of a mitochondriareactive oxygen species pathway. Diabetes, 2009; 58: 954-64
65. Kowluru RA, Chan PS: Oxidative stress and diabetic retinopathy. Exp Diabetes Res, 2007; 2007: 43603
66. Kaneto H, Katakami N, Matsuhisa M, Matsuoka TA: Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis. Mediators Inflamm, 2010; 2010: 453892
67. Lam CS, Benzie IF, Choi SW et al: Relationships among diabetic retinopathy, antioxidants, and glycemic control. Optom Vis Sci, 2011; 88: 251-56
68. Bursell SE, King GL: Can protein kinase C inhibition and vitamin E prevent the development of diabetic vascular complications? Diabetes Res ClinPract, 1999; 45: 169-82
69. Balakumar P, Rohilla A, Krishan P et al: The multifaceted therapeutic potential of benfotiamine. Pharmacol Res. 2010;61: 482-88
70. Du X, Edelstein D, Brownlee M: Oral benfotiamine plus alpha-lipoic acid normalises complication-causing pathways in type 1 diabetes. Diabetologia, 2008; 51: 1930-32
71. Garcia-Medina JJ, Pinazo-Duran MD, Garcia-Medina M et al: A 5-year follow- up of antioxidant supplementation in type 2 diabetic retinopathy. Eur J Ophthalmol, 2011; 21: 637-43
72. Yamagishi S, Matsui T: Advanced glycation end products (AGEs), oxidative stress and diabetic retinopathy. Curr Pharm Biotechnol, 2011; 12: 36228
73. Zoppini G, Negri C, Stoico V et al: Triglyceride-high-density lipoprotein cholesterol is associated with microvascular complications in type 2 diabetes mellitus. Metabolism, 2012; 61: 22-29
74. Gustavsson C, Agardh CD, Zetterqvist AV et al: Vascular cellular adhesion molecule-1 (VCAM-1) expression in mice retinal vessels is affected by both hyperglycemia and hyperlipidemia. PLoS One, 2010; 5: e12699
75. Schwartzman ML, Iserovich P, Gotlinger K et al: Profile of lipid and protein autacoids in diabetic vitreous correlates with the progression of diabetic retinopathy. Diabetes, 2010; 59: 1780-88
76. Keech AC, Mitchell P, Summanen PA et al., FIELD study investigators: Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet, 2007; 370: 1687-97
77. Ansquer JC, Crimet D, Foucher C: Fibrates and statins in the treatment of diabetic retinopathy. Curr Pharm Biotechnol, 2011; 12: 396-405
78. Mohamadin AM, Elberry AA, Abdel Gawad HS et al: Protective Effects of Simvastatin, a Lipid Lowering Agent, against Oxidative Damage in Experimental Diabetic Rats. J Lipids, 2011; 2011: 167958
79. Das UN: Is lipoxins A4 a better alternative to anti-VEGF and anti-TNF-α antibody to prevent and treat age-related macular degeneration, diabetic macular edema and retinopathy? Med SciMonit, 2012; 18(1): LE1-LE2
80. Lim LS, Wong TY: Lipids and diabetic retinopathy. Expert Opin Biol Ther, 2012; 12: 93-105
81. DeBuc DC, Somfai G: Early detection of retinal thickness changes in diabetes using Optical Coherence Tomography. Med Sci Monit, 2010; 16(3): MT15-MT21
82. Weber M, Bonaventure N, Sahel JA: Protective role of excitatory amino acid antagonists in experimental retinal ischemia. Graefes Arch Clin Exp Ophthalmol, 1995; 233: 360-65
83. Vorwerk CK, Lipton SA, Zurakowski D et al: Chronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by memantine. Invest Ophthalmol Vis Sci, 1996; 37: 1618-24
84. Kusari J, Zhou S, Padillo E et al: Effect of memantine on neuroretinal function and retinal vascular changes of streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci, 2007; 48: 5152-59
85. Martin PM, Ola MS, Agarwal N et al: The sigma receptor ligand (+)-pentazocine prevents apoptotic retinal ganglion cell death induced in vitro by homocysteine and glutamate. Brain Res Mol Brain Res, 2004; 123(1-2): 66-75
86. Ola MS, Xu Y, Barber AJ, LaNoue KF: Gabapentin Ameliorates Apoptosis of the Diabetic Rat Retina. Invest Ophthalmol Vis Sci, 2007; 48: E-632
87. Ola MS, Nawaz MI, El-Asrar A et al: Reduced levels of brain derived neurotrophic factor (BDNF) in the serum of diabetic retinopathy patients and in the retina of diabetic rats. Cell MolNeurobiol, 2013; 33(3): 359-67
88. Yamanaka M, Itakura Y, Ono-Kishino M et al: Intermittent administration of brain derived neurotrophic factor (BDNF) ameliorates glucose metabolism and prevents pancreatic exhaustion in diabetic mice. J Biosci Bioeng, 2008; 105: 395-402
89. Yamanaka M, Itakura Y, Tsuchida A et al: Brain-derived neurotrophic factor (BDNF) prevents the development of diabetes in prediabetic mice. Biomed Res, 2008; 29: 147-53
90. Azadi S, Johnson LE, Paquet-Durand F et al: CNTF+BDNF treatment and neuroprotective pathways in the rd1 mouse retina. Brain Res, 2007; 1129: 116-29
91. Chan-Ling T, Baxter L, Afzal A et al: Hematopoietic stem cells provide repair functions after laser-induced Bruch's membrane rupture model of choroidal neovascularization. Am J Pathol, 2006; 168: 1031-44
92. Jonas JB, Witzens-Harig M, Arseniev L, Ho AD: Intravitreal autologous bone marrow-derived mononuclear cell transplantation: a feasibility report Acta Ophthalmol, 2008; 86: 225-26
93. Siqueira RC, Messias A, Voltarelli JC et al: Intravitreal injection of autologous bone marrow-derived mononuclear cells for hereditary retinal dystrophy: a phase I trial. Retina, 2011; 31: 1207-14
94. Siqueira RC, Jorge R: Translational research in retinology. Clin Ophthalmol, 2011; 5: 1493-98
95. Kalluri R, Kanasaki K: RNA interference: generic block on angiogenesis. Nature, 2008; 452: 543-45
96. Murata M, Takanami T, Shimizu S et al: Inhibition of ocular angiogenesis by diced small interfering RNAs (siRNAs) specific to vascular endothelial growth factor (VEGF). Curr Eye Res, 2006; 31: 171-80
97. Jiang J, Xia XB, Xu HZ et al: Inhibition of retinal neovascularization by gene transfer of small interfering RNA targeting HIF-1alpha and VEGF. J Cell Physiol, 2009; 218: 66-74
98. Wilkinson-Berka JL, Lofthouse S, Jaworski K et al: An antisense oligonucleotide targeting the growth hormone receptor inhibits neovascularization in a mouse model of retinopathy. Mol Vis, 2007; 13: 1529-38
99. Forooghian F, Das B: Anti-angiogenic effects of ribonucleic acid interference targeting vascular endothelial growth factor and hypoxia-inducible factor-1alpha. Am J Ophthalmol, 2007; 144: 761-68
100. Shen J, Yang X, Xiao WH et al: Vasohibin is up-regulated by VEGF in the retina and suppresses VEGF receptor 2 and retinal neovascularization. FASEB J, 2006; 20: 723-25
101. A Phase 3, Randomized, Double-masked, Parallel-assignment Study of Intravitreal Bevasiranib Sodium, Administered Every8 or 12 Weeks as Maintenance Therapy Following Three Injections of Lucentis Compared With Lucentis Monotherapy Every 4 Weeks in Patients With Exudative Age-Related Macular Degeneration (AMD). ClinicalTrials.gov identifier NCT00499590
102. Kaiser PK, Symons RC, Shah SM et al., Sirna-027 Study Investigators: RNAibased treatment for neovascular age-related macular degeneration by Sirna-027. Am J Ophthalmol, 2010; 150: 33-39